Ortiz wants audit of stem-cell institute
By Sacramento Business Journal,
Sacramento Business Journal
| 02. 22. 2006
State Sen. Deborah Ortiz and 10 other California legislators have asked for an audit of the California Institute for Regenerative Medicine.
CIRM, which oversees stem-cell research money in the state, was created by Proposition 71, which voters approved in 2004.
Ortiz, a Sacramento Democrat, wrote SB 18, a stem-cell oversight bill vetoed by Gov. Arnold Schwarzenegger, with Sen. George Runner, a Republican from Lancaster. In his veto message, Schwarzenegger called the bill's proposed changes to the law that created the stem-cell institute illegal, and urged legislators to pursue an audit through the Joint Legislative Audit Committee.
Ortiz's letter to the audit committee asks for an audit by Sept. 30, 2006 of CIRM and the Independent Citizens' Oversight Committee that governs it.
Ortiz and the others intended to present their request to the committee on Wednesday in Sacramento, but the hearing was postponed, possibly until March 8, according to Ortiz's office.
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
